Keryx Biopharmaceuticals (KERX) Phase 3 Study of Zerenex Meets Primary Endpoint
Tweet Send to a FriendGet Alerts KERX Hot Sheet
Up)
Trade KERX Now!
Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) announced highly statistically significant positive results From Phase 3 Study of Zerenex for the treatment of hyperphosphatemia in dialysis patient.
The primary endpoint of the study was to determine whether there is a dose response in the change in serum phosphorus from Baseline to Day 28 in the ITT group, using a regression analysis to evaluate this objective.
The study met the primary endpoint, with the regression analysis indicating a highly statistically significant dose response (p<0.0001).
In addition, a statistically significant dose response increase in serum bicarbonate was observed in the study, indicating the potential ability of Zerenex to manage metabolic acidosis, as seen in prior clinical studies with Zerenex.
Read more about the study in the company press release
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
The primary endpoint of the study was to determine whether there is a dose response in the change in serum phosphorus from Baseline to Day 28 in the ITT group, using a regression analysis to evaluate this objective.
The study met the primary endpoint, with the regression analysis indicating a highly statistically significant dose response (p<0.0001).
In addition, a statistically significant dose response increase in serum bicarbonate was observed in the study, indicating the potential ability of Zerenex to manage metabolic acidosis, as seen in prior clinical studies with Zerenex.
Read more about the study in the company press release
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Oncolytics Biotech (ONCY) REOLYSIN w/ REO 020 Met Primary Endpoint in Phase 2
- Peregrine Pharma (PPHM), FDA Reach Agreement Over Bavituximab Phase III Design
- Canaccord Boosts PT on AcelRx (ACRX) to $11; On Track for Sufentanil NDA Submission by Q313
Create E-mail Alert Related Categories
FDA, Hot FDA News
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
